BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325027750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Double Recognition: Smart Communications Named a Leader in IDC MarketScape Reports for Intelligent CCM and Automated Document Generation6.12.2024 15:20:00 CET | Press release
IDC MarketScape Reports Explore the Future of CCM with Focus on AI and Intelligent Forms Smart Communications™, a leading technology company focused on transforming customer conversations, announced today that it has been named a ‘Leader’ in the IDC MarketScape: Worldwide Intelligent Customer Communications Management 2024 Vendor Assessment (doc # US51359124, December 2024). Additionally, the company was recognized as a Leader in the IDC MarketScape: Automated Document Generation and Customer Communications Management 2024 Vendor Assessment (doc # US52111324, December 2024). The IDC MarketScape: Intelligent Customer Communications Management report represents the industry’s evolution toward digital-first, AI-powered solutions that enable organizations to streamline customer interactions, drive personalization and adapt to the growing complexity of data collection and communications across multiple channels. “We believe being named a Leader in the IDC MarketScape: Intelligent Customer C
Third Annual Digital Engineering Awards Honor The Pioneers Transforming Engineering and Technology6.12.2024 11:08:00 CET | Press release
- The 3rd edition of the marquee awards presented in association with ISG, L&T Technology Services, and CNBC-TV18 - Over 230 nominations from leading global organizations and teams across breakthrough technologies, including AI and Gen AI The third annual Digital Engineering Awards brought together over 100 global engineering leaders and standout individual contributors to celebrate excellence in digital engineering. During the awards gala in Dallas, Texas, co-hosted by ISG, L&T Technology Services (LTTS) and CNBC-TV18, 35 leading organizations and 14 individuals from North America, Europe, and Asia Pacific were recognized for their groundbreaking innovations. Their contributions are redefining technology, sustainability, and the future of engineering across the key segments of Mobility, Sustainability, and Tech. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205397523/en/ The 3rd edition of the Digital Engineering Awards
Ryp Labs Crowned the Winner of Lineage’s 2024 Global Food Chain Innovation Challenge5.12.2024 22:35:00 CET | Press release
Ryp Labs awarded $50,000 and invited into executive-led incubator program for its biomimicry solution that increases the shelf-life of fresh produce Lineage, Inc., (NASDAQ: LINE) (the “Company”), the world’s largest global temperature-controlled warehouse REIT, today announced the winner of its Food Chain Innovation Challenge. Ryp Labs, the winner of the San Francisco regional event, was selected for its innovative solution for tackling postharvest food waste, securing the global grand prize of $50,000 and an invitation into a six-month, Lineage executive-led incubator program. Ryp Labs’ winning idea is called StixFresh, a natural and safe formulation that mimics the defense mechanisms of plants to slow down the natural process of fruit spoilage. It can be applied to a variety of surfaces, including food-safe labels and stickers, and has been shown to extend the shelf-life of fresh produce, thereby reducing food waste. The global competition on December 2 convened three regional winner
Mindbreeze is named “a Leader” in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment5.12.2024 19:14:00 CET | Press release
Mindbreeze, a global leader in AI-powered enterprise intelligence, is named a Leader in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment (doc #US51541224, December 2024). Mindbreeze InSpire is transforming the future of enterprise intelligence, revolutionizing how organizations unlock the power of their information. Powered by advanced AI agents, it seamlessly integrates and analyzes structured and unstructured data from diverse systems, turning complexity into clarity. By creating dynamic insight journeys, Mindbreeze InSpire delivers hyper-relevant, context-aware insights tailored to employees’ unique roles and needs—enabling smarter decisions at every level. Beyond streamlining business process transformation, it empowers organizations to fully realize the value of their information ecosystems, driving innovation and securing a competitive edge in today’s fast-paced, data-driven world. Therefore, “Consider Mindbreeze if you are a large en
APRIL Group Continues Its International Expansion by Strengthening Its Presence in China5.12.2024 19:02:00 CET | Press release
APRIL Group is taking a further step forward in its growth by strengthening its presence in Shanghai and across the pan-Asian region to offer its health insurance solutions to people living locally or abroad. APRIL is thus stepping up its international expansion, following the opening in recent months of offices in Dubai in the Middle East and Cologne in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205885654/en/ (Photo: Business Wire) By enhancing its presence in China, the group is solidifying its footprint in Asia, where it now operates in 7 markets (China, Hong Kong, Indonesia, Singapore, Thailand, Vietnam and the Philippines). APRIL International supports individuals and companies in all their international mobility projects, as well as high net worth individuals who benefit from high-quality local healthcare networks. To further develop its presence in China, APRIL international has chosen to draw on the e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom